MAIA CZARNECKI: Open Payments
NPI 1184077885 · LIVERPOOL, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$438 in 17 payments from 9 companies in 2025. Trend: 2023 $1,498 · 2024 $782 · 2025 $438
Food & beverage: $438
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 5 | $220 |
| Janssen Pharmaceuticals, Inc | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 1 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| ABBVIE INC. | 2 | $33 |
| Alkermes, Inc. | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Orexo US, Inc. | 1 | $15 |
| Indivior Inc. | 1 | $15 |
Products named: Epclusa, INVEGA, HETLIOZ, VRAYLAR, UZEDY, ABILIFY MAINTENA, ARISTADA, VIVITROL.
Industry payments across NY — which companies pay providers there.
